Researchers have shown that an experimental treatment for Ebola increased the survival rates of tested mice as
scientists continue searching for ways the global health community can be better prepared for any future outbreaks.
The Ebola outbreak began in West Africa in December 2013 and claimed 10,000 lives. Approximately 25,000 people were infected with the disease before it slowed its spread.
The Food and Drug Administration (FDA) has not approved any vaccine or therapeutic drug that may treat Ebola. Some scientists have created vaccines that may prevent future Ebola infections, while others are concentrating on treatments for patients who have already contracted the disease. Some of the investigational compounds include flu and malaria drugs.
One group of researchers have focused on a class of diazachrysenes, which are small,
molecules that effectively treat botulinum neurotoxin, the most serious bacterial toxin. Scientists want to screen this class for potential Ebola drug candidates.
Researchers have discovered potential drug candidates for a new Ebola treatment that successfully increase the survival rates of 70 to 90 percent of mice subjects.
Further details about the study are available in ACS Infectious Diseases journal.